

Characteristics of Nutritional Status and the Effect of Pre-transplant Branched-chain Amino Acid Administration in Patients Undergoing Living Donor Liver Transplantation

Ahmed Hammad^{1,2}, Toshimi Kaido^{1*}, Shintaro Yagi¹, Hideaki Okajima¹ and Shinji Uemoto¹

¹Division of Hepato-Biliary-Pancreatic and Transplant Surgery, Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, Japan

²Department of Surgery, Mansoura University, Mansoura, Egypt

***Corresponding author:** Toshimi Kaido, Division of Hepato-Biliary-Pancreatic and Transplant Surgery, Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan, Tel: +81-75-751-4323; Fax: +81-75-751-4348; E-mail: kaido@kuhp.kyoto-u.ac.jp

LDL (1.33 ± 0.13 vs 1.33 ± 0.13, P = 0.99), BCAA (12.45 ± 1.25 vs 12.45 ± 1.25, P = 0.99), and BCAA+ (12.45 ± 1.25 vs 12.45 ± 1.25, P = 0.99).

Subgroups assignment

Subgroups assignment: LDL (1.33 ± 0.13 vs 1.33 ± 0.13, P = 0.99), BCAA (12.45 ± 1.25 vs 12.45 ± 1.25, P = 0.99), and BCAA+ (12.45 ± 1.25 vs 12.45 ± 1.25, P = 0.99).

Analyzed parameters

Analyzed parameters: LDL (1.33 ± 0.13 vs 1.33 ± 0.13, P = 0.99), BCAA (12.45 ± 1.25 vs 12.45 ± 1.25, P = 0.99), and BCAA+ (12.45 ± 1.25 vs 12.45 ± 1.25, P = 0.99).

Subgroups assignment: LDL (1.33 ± 0.13 vs 1.33 ± 0.13, P = 0.99), BCAA (12.45 ± 1.25 vs 12.45 ± 1.25, P = 0.99), and BCAA+ (12.45 ± 1.25 vs 12.45 ± 1.25, P = 0.99).

Subgroups assignment: LDL (1.33 ± 0.13 vs 1.33 ± 0.13, P = 0.99), BCAA (12.45 ± 1.25 vs 12.45 ± 1.25, P = 0.99), and BCAA+ (12.45 ± 1.25 vs 12.45 ± 1.25, P = 0.99).


Statistical analysis

Statistical analysis: LDL (1.33 ± 0.13 vs 1.33 ± 0.13, P = 0.99), BCAA (12.45 ± 1.25 vs 12.45 ± 1.25, P = 0.99), and BCAA+ (12.45 ± 1.25 vs 12.45 ± 1.25, P = 0.99).

	Variable	90-days OS	P
Recipient Age (y)	<60 (n=88)	86%	0.283
	60 (n=41)	91%	
Donor Age (y)	<50 (n=93)	91%	0.335
	50 (n=36)	85%	
Sex	Male (n=63)	91%	0.143
	Female (n=66)	83%	
Original disease	HCC (n=36)	81%	0.144
	Non-HCC (n=93)	90%	
ABO blood type	Compatible (n=92)	90%	0.087
	Incompatible (n=37)	81%	
Child-Pugh classification	A, B (n=51)	91%	0.227
	C (n=78)	84%	
MELD score	<20 (n=69)	92%	0.069
	20 (n=50)	81%	
GRWR	<0.8% (n=36)		
	0.8% (n=93)	91%	
Graft	Right lobe (n=70)	88%	0.535
	Left lobe (n=59)	86%	
Operative time (h)	<12 (n=30)	89%	0.09
	12 (n=99)	83%	
Operative blood loss (L)	<10 (n=88)	92%	0.079
	10 (n=41)	81%	
Pre-transplant zinc level (µg/dL)	<39 (n=58)	84%	0.634
	39 (n=71)	88%	
Pre-transplant prealbumin level (mg/dL)	<5.4 (n=64)	83%	0.343
	5.4 (n=65)	90%	
Pre-transplant BCAA level (µmol/L)	<375.2 (n=62)	81%	0.476
	375.2 (n=67)	85%	
Pre-transplant BTR	<2.92 (n=60)	85%	0.786
	2.92 (n=69)	87%	
Pre-transplant tyrosine (µmol/L)	<131.7 (n=63)	89%	0.1
	131.7 (n=66)	85%	
Pre-transplant total lymphocyte count (/µL)	<700 (n=61)	85%	0.698
	700 (n=68)	87%	
Pre-transplant ammonia level (µg/dL)	<87 (n=61)	90%	0.5
	87 (n=68)	85%	
BCAA supplementation before admission	With (n=66)	91%	0.329
	Absent (n=63)	86%	

†OS: Overall Survival; BCAA: Branched-Chain Amino Acids; BTR: BCAA-To-Tyrosine Ratio; GRWR: Graft-To-Recipient Body Weight Ratio; HCC: Hepatocellular Carcinoma; MELD: Model for End-Stage Liver Disease; LDLT: Living Donor Liver Transplantation

Table 3: Univariate analysis of factors affecting post-transplant patient survival.



Citation: Hammad A, Kaido T, Yagi S, Okajima H, Uemoto S (2016) Characteristics of Nutritional Status and the Effect of Pre-Transplant Branched-Chain Amino Acid Administration in Patients Undergoing Living Donor Liver Transplantation. J Clin Exp Transplant 1: 101.
